Last Price
37.75
Today's Change
-0.77 (1.99%)
Day's Change
37.70 - 39.31
Trading Volume
502,988
Market Cap
2 Billion
Shares Outstanding
59 Million
Avg Volume
682,053
Avg Price (50 Days)
39.76
Avg Price (200 Days)
38.54
PE Ratio
13.78
EPS
2.74
Earnings Announcement
25-Feb-2025
Previous Close
38.52
Open
38.36
Day's Range
37.7 - 39.31
Year Range
24.22 - 48.89
Trading Volume
528,156
1 Day Change
-2.00%
5 Day Change
-3.01%
1 Month Change
-0.89%
3 Month Change
-20.69%
6 Month Change
4.25%
Ytd Change
-3.16%
1 Year Change
46.55%
3 Year Change
34.82%
5 Year Change
350.48%
10 Year Change
222.65%
Max Change
222.65%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.